Panther® System

    The foundation for assay consolidation, future scalability and growth

    Add the Panther system to your lab and the capability to consolidate menu on a fully automated system, load samples in any order at any time, eliminate batch constraints and decrease turnaround time.

    Labor savings

    • Broad assay menu on a single platform allows consolidation and the ability to run more tests per full-time employee

    • Full automation allows samples to be loaded at the end of the day and run labor free after hours

    • Ability to run multiple test orders from the same patient sample at the same time expedites results

    • Ability to load primary sample tubes eliminates manual transfer of specimen

    Time savings

    • Flexible sample loading provides control over workflow by either random access or batch processing

    • Programmable/automated maintenance allows tasks to run labor free during non-operational hours

    • STAT samples can be loaded at any time, allowing urgent samples to be prioritized

    • Specialized reports to automate tracking and trending of QC and results: Levey-Jennings, Prevalence Reports, Sample History Report, Sample Curve Report and Maintenance Checklist

    • Add on additional IVD menu without disrupting existing workflow

    Cost savings

    • Small footprint gives labs the ability to run more tests per sq ft and options for scalability and redundancy

    • Consolidation of platforms helps reduce LIS connection costs and streamline tech training and competencies

    • Consumables designed to reduce waste (tubes vs plate) and included in price-per-test provide transparency

    • Liquid waste is nonhazardous and does not require special handling*

    • QC only required every 24 hours, or with a new kit, reducing time and costs

    *Follow local and state guidelines

    Consolidate your assay menu

    The Aptima® assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.

    * The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
    † In Development and not for sale

    Related products

    Panther® System

    The foundation for assay consolidation, future scalability and growth

    Add the Panther system to your lab and the capability to consolidate menu on a fully automated system, load samples in any order at any time, eliminate batch constraints and decrease turnaround time.

    Labour savings

    • Broad assay menu on a single platform allows consolidation and the ability to run more tests per full-time employee

    • Full automation allows samples to be loaded at the end of the day and run labor free after hours

    • Ability to run multiple test orders from the same patient sample at the same time expedites results

    • Ability to load primary sample tubes eliminates manual transfer of specimen

    Time savings

    • Flexible sample loading provides control over workflow by either random access or batch processing

    • Programmable/automated maintenance allows tasks to run labor free during non-operational hours

    • STAT samples can be loaded at any time, allowing urgent samples to be prioritized

    • Specialized reports to automate tracking and trending of QC and results: Levey-Jennings, Prevalence Reports, Sample History Report, Sample Curve Report and Maintenance Checklist

    • Add on additional IVD menu without disrupting existing workflow

    Cost savings

    • Small footprint gives labs the ability to run more tests per sq ft and options for scalability and redundancy

    • Consolidation of platforms helps reduce LIS connection costs and streamline tech training and competencies

    • Consumables designed to reduce waste (tubes vs plate) and included in price-per-test provide transparency

    • Liquid waste is nonhazardous and does not require special handling

    • QC only required every 24 hours, or with a new kit, reducing time and costs

    *Follow local and state guidelines

    Consolidate your assay menu

    The Aptima® assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.

    Women's Health

    CT/NG
    CT
    NG
    MG
    TV

    BVCandida/TV
    HSV 1 & 2
    HPV
    HPV genotype 16 18/45

    Zika Virus*

    Infectious Disease

    HIV-1 Quant Dx
    HCV Quant Dx
    HBV Quant
    CMV†
    SARS-CoV-2*


     

    * The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
    † In Development and not for sale

    Related products